Please login to the form below

Not currently logged in
Email:
Password:

Amicus Therapeutics

This page shows the latest Amicus Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Orchard raises $150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval

Daily Brief: Orchard raises $150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval

Gene therapy trend grows, new rival for Fabrazyme. Orchard Therapeutics raises $150m to advance gene therapy pipeline. ... Amicus’s Galafold gains FDA approval, set to rival Fabrayzme. Amicus Therapeutics has received FDA approval for Galafold, the

Latest news

  • Lucid picks up rare disease and orphan drugs trophy at PMEA 2017 Lucid picks up rare disease and orphan drugs trophy at PMEA 2017

    Narrowly missing first place, but still achieving a highly commended status on the night was Amicus Therapeutics UK for its work on rare diseases. ... Judges said: “Amicus did a very good job for a small outfit in the start-up phase and they showed an

  • Amicus Therapeutics launches Fabry treatment Galafold in Italy Amicus Therapeutics launches Fabry treatment Galafold in Italy

    Follows publication of Ministry of Health's reimbursement guidelines. US biotech Amicus Therapeutics has launched its new Fabry disease treatment Galafold (migalastat) in Italy after winning reimbursement coverage. ... Amicus’ therapy is a

  • SMC approves Opdivo combo as first-line skin cancer treatment SMC approves Opdivo combo as first-line skin cancer treatment

    Also backs Gilead’s Epclusa, Baxalta’s Oncaspar, AZ’s Lynparza and Amicus’ Galafold. ... Amicus Therapeutics' Galafold (migalastat) has also received the go-ahead, and has been sanctioned by the SMC for the treatment of adults with Fabry disease,

  • NICE backs Amicus Therapeutics’ Galafold NICE backs Amicus Therapeutics’ Galafold

    The committee gave Amicus Therapeutics' genetic disorder treatment the provisional green light, bringing UK patients one step closer to an orally administered alternative to the standard fortnightly injections. ... The regulator has agreed a confidential

  • GSK gene therapy tops CHMP recommendations GSK gene therapy tops CHMP recommendations

    Amicus Therapeutics got a green light from the CHMP for Galafold (migalastat) as the first oral treatment for Fabry disease, which is caused by a deficiency in alpha-galactosidase A. ... The positive opinion marks a turnaround for migalastat, which had

More from news
Approximately 5 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2013 Pharma deals during November 2013

    It was clearly a good news – bad news day for Amicus Therapeutics this month when two press releases were released. ... for Pompe disease. Amicus also announced plans to cut costs as part of a restructuring to focus on enzyme replacement therapies.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics